Optimi Health Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand
Portfolio Pulse from
Optimi Health Corp. has successfully dosed the first patients in a landmark study using its natural psilocybin extract in New Zealand. The study aims to address methamphetamine addiction through indigenous frameworks.
January 13, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optimi Health Corp. has initiated a significant study in New Zealand using its natural psilocybin extract to tackle methamphetamine addiction, marking a milestone in its product application.
The initiation of a landmark study using Optimi's psilocybin extract in New Zealand is a significant step in the application of their product, potentially increasing demand and investor interest. This could positively impact OPTHF's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90